Status:
COMPLETED
Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)
Lead Sponsor:
Celltrion
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
This is the trial to see how our product is similar to remicade by comparing the results of blood samples when co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose and...
Eligibility Criteria
Inclusion
- diagnosed with active rheumatoid arthritis
- at least 3 months of treatment with methotrexate
Exclusion
- have allergies to infliximab
- serious infection
Key Trial Info
Start Date :
October 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
617 Patients enrolled
Trial Details
Trial ID
NCT01217086
Start Date
October 1 2010
End Date
July 1 2012
Last Update
March 12 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanyang University Medical Center
Seoul, South Korea